News item

Archive of: 2009

  • National Commissioning Consultation

    The Specialised Healthcare Alliance welcomes the Department of Health’s consultation on measures to strengthen national commissioning, including the approach to funding decisions for very specialised new technologies. The rationale for the proposals and the parallel development of an ethical framework chime closely with the results of the Alliance’s conference on high cost treatments in November 2008 and subsequent work. We will be considering the document carefully before submitting our comments by the closing date of 19th February 2010.

  • Health Select Committee

    The Specialised Healthcare Alliance has submitted evidence to the House of Commons Health Select Committee, which is conducting an inquiry into NHS commissioning. The Alliance is delighted that the Committee is looking at specialised commissioning as part of its terms of reference for the inquiry given its importance to the large number of people affected by rare diseases and other complex conditions.

  • General Election Prospectus

    The Specialised Healthcare Alliance has reviewed its priorities for the next Parliament, which are summarised in the attached document. In particular, the Alliance wishes to see:

    • A minister with responsibility for specialised services;
    • Comprehensive designation of specialised providers with robust pooled budgets to pay for them;
    • Proper regulatory oversight of specialised commissioning through the Care Quality Commission;
    • An ethical framework applied consistently across the NHS in relation to funding decisions.
  • Rare diseases, complex conditions and the limits of localism

    p.In the 11 th May edition of the House Magazine, Baroness Pitkeathley seeks support across all parties for some key Alliance objectives up to and beyond the next General Election.

  • High cost treatments

    Following the Alliance’s successful conference at the Royal Society of Arts on 18 th November 2008, members have agreed a framework of ethical and other considerations to help inform best practice in decision-making on high cost treatments at all levels within the NHS.